153 related articles for article (PubMed ID: 33651355)
1. PCA3 in Prostate Cancer.
Gunelli R; Fragalà E; Fiori M
Methods Mol Biol; 2021; 2292():105-113. PubMed ID: 33651355
[TBL] [Abstract][Full Text] [Related]
2. Multiparametric magnetic resonance imaging of the prostate can improve the predictive value of the urinary prostate cancer antigen 3 test in patients with elevated prostate-specific antigen levels and a previous negative biopsy.
Sciarra A; Panebianco V; Cattarino S; Busetto GM; De Berardinis E; Ciccariello M; Gentile V; Salciccia S
BJU Int; 2012 Dec; 110(11):1661-5. PubMed ID: 22564540
[TBL] [Abstract][Full Text] [Related]
3. Clinical evaluation of prostate cancer gene 3 score in diagnosis among Chinese men with prostate cancer and benign prostatic hyperplasia.
Huang J; Reilly KH; Zhang HZ; Wang HB
BMC Urol; 2015 Dec; 15():118. PubMed ID: 26628213
[TBL] [Abstract][Full Text] [Related]
4. Rational approach to implementation of prostate cancer antigen 3 into clinical care.
Wang R; Chinnaiyan AM; Dunn RL; Wojno KJ; Wei JT
Cancer; 2009 Sep; 115(17):3879-86. PubMed ID: 19517474
[TBL] [Abstract][Full Text] [Related]
5. Progensa™ PCA3 test for prostate cancer.
Durand X; Moutereau S; Xylinas E; de la Taille A
Expert Rev Mol Diagn; 2011 Mar; 11(2):137-44. PubMed ID: 21405964
[TBL] [Abstract][Full Text] [Related]
6. Combination of Prostate Cancer Antigen 3 and Prostate-Specific Antigen Improves Diagnostic Accuracy in Men at Risk of Prostate Cancer.
Cao L; Lee CH; Ning J; Handy BC; Wagar EA; Meng QH
Arch Pathol Lab Med; 2018 Sep; 142(9):1106-1112. PubMed ID: 29547000
[TBL] [Abstract][Full Text] [Related]
7. PCA3 sensitivity and specificity for prostate cancer detection in patients with abnormal PSA and/or suspicious digital rectal examination. First Latin American experience.
Ramos CG; Valdevenito R; Vergara I; Anabalon P; Sanchez C; Fulla J
Urol Oncol; 2013 Nov; 31(8):1522-6. PubMed ID: 22687565
[TBL] [Abstract][Full Text] [Related]
8. The novel prostate cancer antigen 3 (PCA3) biomarker.
Bourdoumis A; Papatsoris AG; Chrisofos M; Efstathiou E; Skolarikos A; Deliveliotis C
Int Braz J Urol; 2010; 36(6):665-8; discussion 669. PubMed ID: 21176272
[TBL] [Abstract][Full Text] [Related]
9. Urinary Prostate Cancer Antigen 3 as a Tumour Marker: Biochemical and Clinical Aspects.
Schmid M; Hansen J; Chun FK
Adv Exp Med Biol; 2015; 867():277-89. PubMed ID: 26530372
[TBL] [Abstract][Full Text] [Related]
10. Utility of PCA3 in patients undergoing repeat biopsy for prostate cancer.
Wu AK; Reese AC; Cooperberg MR; Sadetsky N; Shinohara K
Prostate Cancer Prostatic Dis; 2012 Mar; 15(1):100-5. PubMed ID: 22042252
[TBL] [Abstract][Full Text] [Related]
11. Urine TMPRSS2:ERG fusion transcript integrated with PCA3 score, genotyping, and biological features are correlated to the results of prostatic biopsies in men at risk of prostate cancer.
Cornu JN; Cancel-Tassin G; Egrot C; Gaffory C; Haab F; Cussenot O
Prostate; 2013 Feb; 73(3):242-9. PubMed ID: 22821767
[TBL] [Abstract][Full Text] [Related]
12. Current biomarkers for diagnosing of prostate cancer.
Stephan C; Jung K; Ralla B
Future Oncol; 2015; 11(20):2743-55. PubMed ID: 26358139
[TBL] [Abstract][Full Text] [Related]
13. Prostate cancer detection rate at repeat saturation biopsy: PCPT risk calculator versus PCA3 score versus case-finding protocol.
Pepe P; Aragona F
Can J Urol; 2013 Feb; 20(1):6620-4. PubMed ID: 23433132
[TBL] [Abstract][Full Text] [Related]
14. [Value of PCA3 urinary test for prostate biopsy decision: the Lyon-Sud University Hospital experience].
Vlaeminck-Guillem V; Campos-Fernandes JL; Champetier D; Chikh K; Decaussin-Petrucci M; Devonec M; Gobeaux N; Paparel P; Perrin P; Rodriguez-Lafrasse C; Ruffion A
Ann Biol Clin (Paris); 2011; 69(1):31-9. PubMed ID: 21463993
[TBL] [Abstract][Full Text] [Related]
15. Prostate health index and prostate cancer gene 3 score but not percent-free Prostate Specific Antigen have a predictive role in differentiating histological prostatitis from PCa and other nonneoplastic lesions (BPH and HG-PIN) at repeat biopsy.
De Luca S; Passera R; Fiori C; Bollito E; Cappia S; Mario Scarpa R; Sottile A; Franco Randone D; Porpiglia F
Urol Oncol; 2015 Oct; 33(10):424.e17-23. PubMed ID: 26162485
[TBL] [Abstract][Full Text] [Related]
16. Optimizing prostate cancer screening; prospective randomized controlled study of the role of PSA and PCA3 testing in a sequential manner in an opportunistic screening program.
Rubio-Briones J; Casanova J; Dumont R; Rubio L; Fernandez-Serra A; Casanova-Salas I; Domínguez-Escrig J; Ramírez-Backhaus M; Collado A; Gómez-Ferrer A; Iborra I; Monrós JL; Ricós JV; Solsona E; Salas D; Martínez F; Lopez-Guerrero JA
Actas Urol Esp; 2014 May; 38(4):217-23. PubMed ID: 24169211
[TBL] [Abstract][Full Text] [Related]
17. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer.
Hessels D; Klein Gunnewiek JM; van Oort I; Karthaus HF; van Leenders GJ; van Balken B; Kiemeney LA; Witjes JA; Schalken JA
Eur Urol; 2003 Jul; 44(1):8-15; discussion 15-6. PubMed ID: 12814669
[TBL] [Abstract][Full Text] [Related]
18. Prostate health index (phi) and prostate cancer antigen 3 (PCA3) significantly improve diagnostic accuracy in patients undergoing prostate biopsy.
Perdonà S; Bruzzese D; Ferro M; Autorino R; Marino A; Mazzarella C; Perruolo G; Longo M; Spinelli R; Di Lorenzo G; Oliva A; De Sio M; Damiano R; Altieri V; Terracciano D
Prostate; 2013 Feb; 73(3):227-35. PubMed ID: 22821756
[TBL] [Abstract][Full Text] [Related]
19. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.
Tomlins SA; Day JR; Lonigro RJ; Hovelson DH; Siddiqui J; Kunju LP; Dunn RL; Meyer S; Hodge P; Groskopf J; Wei JT; Chinnaiyan AM
Eur Urol; 2016 Jul; 70(1):45-53. PubMed ID: 25985884
[TBL] [Abstract][Full Text] [Related]
20. [The role of a single PCA3 test before a first negative prostate biopsy: 5-year follow-up].
Bernardeau S; Charles T; Fromont-Hankard G; Irani J
Prog Urol; 2017 Apr; 27(5):325-330. PubMed ID: 28385586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
